RxDoctor Payments Data

Vangel Quilon, NP

Family · Portsmouth, VANPI 1679090492

Payments from drug & device makers

$10,229in general payments, 2019–2025

Across 357 payments — averaging $28.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AbbVie$1K
  • Biogen$582
  • Teva Pharmaceuticals USA, Inc.$563
  • Lundbeck LLC$495
  • Biohaven Pharmaceuticals, Inc.$419
  • plus $5K from 48 others

What the payments were for

  • Speaking & faculty fees$1,81518%
  • Food & beverage$8,20880%
  • Education$2052%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,229 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Medicare billing

Part B allowed, 2024
$516,415
Medicare patients
453
Services billed
86,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine16$192,430
Aimovig AutoinjectorErenumab-Aooe40$33,440
Emgality PenGalcanezumab-Gnlm30$30,134
QuliptaAtogepant28$30,008
Ajovy AutoinjectorFremanezumab-Vfrm27$27,409
Nurtec OdtRimegepant Sulfate22$20,258
UbrelvyUbrogepant11$15,943
Oxtellar XrOxcarbazepine12$13,837
DayvigoLemborexant23$7,172
Lacosamide25$4,779
Pregabalin121$2,778
Mycophenolate Mofetil11$2,694
Dimethyl Fumarate12$2,520
Gabapentin233$2,292
Memantine Hcl62$1,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$563$192,43016 claims
AbbVieQulipta, Ubrelvy$1,285$45,95139 claims
PfizerNurtec Odt$345$20,25822 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$21$13,83712 claims
Eisai Inc.Dayvigo$204$7,17223 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$54$2,69411 claims
Upsher-smith Laboratories LLCTopiramate$13$78454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Portsmouth

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →